METTL7B is a novel prognostic biomarker of lower-grade glioma based on pan-cancer analysis

Cancer Cell International

Lei Wang¹  Caiping Ren¹  Hecheng Zhu²  Ming Zhao²  Wen Yin³  Quanwei Zhou³  Dongcheng Xie³  Zhipeng Jiang³  Can Li³  Zhaoqi Xin³  Youwei Guo³  Yudong Cao³  Xingjun Jiang³  Yirui Kuang³  Zhaoping Wu³  Jun Tan³  Hailong Huang³ 

[1]Cancer Research Institute, Collaborative Innovation Center for Cancer Medicine, The Key Laboratory for Carcinogenesis of Chinese Ministry of Health and the Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, School of Basic Medical Science, Central South University, Changsha, Hunan, People’s Republic of China

[2]Changsha Kexin Cancer Hospital, 410205, Changsha, Hunan, China

[3]Department of Neurosurgery, Xiangya Hospital of Central South University, 410008, Changsha, Hunan, China

关键词: Glioma;    Methyltransferase-like 7B;    Pan-cancer analysis;    Prognostic markers;    Epithelial–mesenchymal transition (EMT);    Immune cell infiltration;   

DOI  :  10.1186/s12935-021-02087-4

来源: Springer

【 摘 要 】

Methyltransferase-like 7B (METTL7B) is a member of the methyltransferase-like protein family that plays an important role in the development and progression of tumors. However, its prognostic value and the correlation of METTL7B expression and tumor immunity in some cancers remain unclear. By analyzing online data, we found that METTL7B is abnormally overexpressed in multiple human tumors and plays an important role in the overall survival (OS) of patients with 8 cancer types and disease-free survival (DFS) of patients with 5 cancer types. Remarkably, METTL7B expression was positively correlated with the OS and DFS of patients with lower-grade glioma (LGG). In addition, a positive correlation between METTL7B expression and immune cell infiltration in LGG was observed. Moreover, we identified a strong correlation between METTL7B expression and immune checkpoint gene expression in kidney chromophobe (KICH), LGG and pheochromocytoma and paraganglioma (PCPG). Furthermore, METTL7B was involved in the extracellular matrix (ECM) and immune-related pathways in LGGs. Finally, in vitro experiments showed that knockdown of METTL7B inhibited the growth, migration, invasion and the epithelial–mesenchymal transition (EMT) of LGG cells. METTL7B expression potentially represents a novel prognostic biomarker due to its significant association with immune cell infiltration in LGG.

【 授权许可】

CC BY